RESUMEN
Antibody levels to outer surface proteins C and F (OspC and OspF, respectively) in sera collected from laboratory Beagle dogs at 1, 2, and 4 months after challenge with infected black-legged ticks (Ixodes scapularis) were determined. Each dog was confirmed by culture to harbor Borrelia burgdorferi in the skin (n = 10) or the skin and joints (n = 14). Significant levels of immunoglobulin M (Ig)M or IgG anti-OspC antibodies were detected in single serum samples from only 3 (13%) dogs. Similarly, IgM anti-OspF antibodies were detected in only 1 (4%) serum sample collected from a dog with B. burgdorferi in the skin and joints. In contrast, 4 (29%) dogs with skin and joint infections produced IgG anti-OspF antibodies after 2 months, and the response expanded to include 2 (20%) dogs with skin infection and 4 additional dogs with skin and joint infections (overall sensitivity = 62%) after 4 months. The findings failed to support the utility of OspC-based antibody tests for diagnosing canine Lyme disease, but demonstrated that dogs with B. burgdorferi colonizing joint tissue most often produced significant levels of IgG anti-OspF antibodies. Therefore, additional studies to more thoroughly evaluate the clinical utility of OspF-based antibody tests are warranted.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/inmunología , Proteínas de la Membrana Bacteriana Externa/inmunología , Borrelia burgdorferi/inmunología , Enfermedades de los Perros/diagnóstico , Lipoproteínas/inmunología , Enfermedad de Lyme/veterinaria , Animales , Formación de Anticuerpos , Enfermedades de los Perros/microbiología , Perros , Femenino , Ixodes/microbiología , Enfermedad de Lyme/diagnóstico , MasculinoRESUMEN
Beagles received placebo or ospA- and ospB-negative Borrelia burgdorferi before a tick challenge. A total of 28 (41%) ticks and skin biopsy specimens from each control dog (n = 10) contained B. burgdorferi. In contrast, 12 (19%) ticks recovered from the vaccine recipients (n = 10) were infected (P = 0.0077), and 5 dogs yielded spirochetes from the skin biopsy specimens (P = 0.0325). In addition, 9 (90%) placebo recipients and 4 (40%) vaccine recipients developed joint abnormalities (P = 0.0573). Therefore, vaccination with the ospA- and ospB-negative spirochete provided significant protection against Lyme disease.
Asunto(s)
Vacunas Bacterianas/inmunología , Borrelia burgdorferi/inmunología , Enfermedades de los Perros/inmunología , Enfermedades de los Perros/prevención & control , Enfermedad de Lyme/veterinaria , Vacunación/métodos , Animales , Antígenos Bacterianos/genética , Antígenos de Superficie , Proteínas de la Membrana Bacteriana Externa/genética , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/genética , Borrelia burgdorferi/genética , Perros , Lipoproteínas/deficiencia , Enfermedad de Lyme/inmunología , Enfermedad de Lyme/prevención & control , Placebos , Resultado del Tratamiento , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/genética , Vacunas Atenuadas/inmunologíaRESUMEN
Canine influenza virus (CIV) is an emerging pathogen that causes acute respiratory disease in dogs. As with any communicable disease, dog-to-dog transmission of CIV occurs when infected dogs come in contact with other susceptible dogs. We demonstrate that CIV transmission occurs readily from CIV-infected dogs to susceptible dogs following co-mingling. Four experimentally infected dogs were co-mingled with a group of eight CIV-negative dogs at 1 day post-infection and both groups were observed for CIV-associated respiratory disease. The onset of clinical signs, virus shedding, seroconversion, and appearance of lung lesions were observed earlier in experimentally infected dogs; however, the severity of the clinical signs and lung lesions were very similar in both groups. One hundred percent of the experimentally infected dogs and 75% of the contact-exposed dogs excreted virus in their nasal secretions. Additionally, 100% of experimentally infected dogs and 75% of the contact-exposed dogs exhibited varying degrees of pneumonia. Our study results demonstrate that CIV spreads readily from infected dogs to other susceptible dogs through direct contact.
Asunto(s)
Enfermedades de los Perros/transmisión , Subtipo H3N8 del Virus de la Influenza A , Infecciones por Orthomyxoviridae/veterinaria , Animales , Enfermedades de los Perros/patología , Enfermedades de los Perros/virología , Perros , Pulmón/patología , Pulmón/virología , Nariz/virología , Infecciones por Orthomyxoviridae/patología , Infecciones por Orthomyxoviridae/transmisión , Infecciones por Orthomyxoviridae/virología , Factores de Tiempo , Tráquea/virología , Esparcimiento de VirusRESUMEN
Laboratory-reared beagles were vaccinated with a placebo or a bacterin comprised of Borrelia burgdorferi S-1-10 and ospA-negative/ospB-negative B. burgdorferi 50772 and challenged after 1 year with B. burgdorferi-infected Ixodes scapularis ticks. For the placebo recipients, spirochetes were recovered from 9 (60%) skin biopsy specimens collected after 1 month, and the organisms persisted in the skin thereafter. Ten (67%) dogs also developed joint infection (3 dogs), lameness or synovitis (7 dogs), or B. burgdorferi-specific antibodies (8 dogs). For the vaccine recipients, spirochetes were recovered from 6 (40%) skin biopsy specimens collected after 1 month. However, subsequent biopsy specimens were negative, and the dogs failed to develop joint infection (P = 0.224), lameness/synovitis (P = 0.006), or Lyme disease-specific antibody responses (P = 0.002). The bacterin provided a high level of protection for 1 year after immunization, and the addition of the OspC-producing B. burgdorferi 50772 provided enhanced protection.
Asunto(s)
Borrelia burgdorferi/inmunología , Enfermedades de los Perros/prevención & control , Vacunas contra Enfermedad de Lyme/inmunología , Enfermedad de Lyme/veterinaria , Animales , Anticuerpos Antibacterianos/sangre , Artritis Infecciosa/microbiología , Artritis Infecciosa/prevención & control , Biopsia , Borrelia burgdorferi/aislamiento & purificación , Borrelia burgdorferi/patogenicidad , Perros , Ixodes/microbiología , Enfermedad de Lyme/prevención & control , Vacunas contra Enfermedad de Lyme/administración & dosificación , Placebos/administración & dosificación , Enfermedades Cutáneas Bacterianas/microbiología , Enfermedades Cutáneas Bacterianas/prevención & control , Factores de TiempoRESUMEN
Canine influenza virus (CIV) subtype H3N8 is an emerging pathogen with sustained horizontal transmission in the dog population in the United States. This study evaluated the efficacy of an inactivated CIV vaccine in 6- to 8-week-old beagle pups challenged with virulent CIV. One group of CIV-seronegative pups was vaccinated with two doses of a CIV vaccine 3 weeks apart; a second group of pups received adjuvanted placebo as a control. Blood samples were collected at various times to determine antibody titers. All pups were challenged with a virulent CIV isolate 13 days after the second vaccination and monitored for clinical signs of respiratory disease, virus shedding, and lung consolidation. Vaccinated pups developed hemagglutination inhibition antibody titers after vaccination. The severity of clinical signs (P < .001) and the magnitude and duration of virus shedding (P < .0001) were significantly lower in vaccinated pups compared with control pups. These results demonstrate that the CIV vaccine used in this study provides protection against virulent CIV challenge in dogs.
Asunto(s)
Enfermedades de los Perros/prevención & control , Subtipo H3N8 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/normas , Infecciones por Orthomyxoviridae/veterinaria , Animales , Anticuerpos Antivirales/sangre , Antígenos Virales/análisis , Perros , Femenino , Pruebas de Inhibición de Hemaglutinación/veterinaria , Inmunohistoquímica/veterinaria , Subtipo H3N8 del Virus de la Influenza A/aislamiento & purificación , Vacunas contra la Influenza/inmunología , Pulmón/patología , Pulmón/virología , Masculino , Infecciones por Orthomyxoviridae/patología , Infecciones por Orthomyxoviridae/prevención & control , Infecciones por Orthomyxoviridae/virología , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/normas , Esparcimiento de VirusRESUMEN
Groups of 15 laboratory-bred beagles were vaccinated and boosted with either a placebo or adjuvanted bivalent bacterin comprised of a traditional Borrelia burgdorferi strain and a unique ospA- and ospB-negative B. burgdorferi strain that expressed high levels of OspC and then challenged with B. burgdorferi-infected Ixodes scapularis ticks. The vaccinated dogs produced high titers of anti-OspA and anti-OspC borreliacidal antibodies, including borreliacidal antibodies specific for an epitope within the last seven amino acids at the OspC carboxy terminus (termed OspC7) that was conserved among pathogenic Borrelia genospecies. In addition, spirochetes were eliminated from the infected ticks that fed on the bacterin recipients, B. burgdorferi was not isolated from the skin or joints, and antibody responses associated specifically with canine infection with B. burgdorferi were not produced. In contrast, B. burgdorferi was recovered from engorged ticks that fed on 13 (87%) placebo-vaccinated dogs (P<0.0001), skin biopsy specimens from 14 (93%) dogs (P<0.0001), and joint tissue specimens from 8 (53%) dogs (P=0.0022). In addition, 14 (93%) dogs developed specific antibody responses against B. burgdorferi proteins, including 11 (73%) with C6 peptide antibodies (P<0.0001). Moreover, 10 (67%) dogs developed Lyme disease-associated joint abnormalities (P<0.0001), including 4 (27%) dogs that developed joint stiffness or lameness and 6 (40%) that developed chronic joint inflammation (synovitis). The results therefore confirmed that the bacterin provided a high level of protection against Lyme disease shortly after immunization.